results
phase
signal
study
huntington
disease
support
potential
cognitive
benefit
pepinemab
key
cognitive
endpoints
trending
towards
reach
statistical
significance
early
manifest
population
overall
study
meet
endpoints
results
support
continued
development
alzheimer
disease
huntington
disease
patients
greater
cognitive
deficits
company
host
investor
conference
call
today
september
edt
access
call
webcast
please
click
rochester
globe
newswire
vaccinex
nasdaq
vcnx
biotechnology
company
pioneering
differentiated
approach
treating
cancer
neurodegenerative
disease
inhibition
today
announced
topline
results
early
manifest
treatment
arm
cohort
phase
signal
trial
lead
clinical
candidate
pepinemab
patients
early
manifest
prodromal
huntington
disease
hd
maurice
zauderer
president
chief
executive
officer
vaccinex
remarked
trial
results
hd
affects
multiple
regions
brain
disease
progression
impacts
many
critical
functions
including
cognition
motor
activity
results
reported
today
strongly
support
cognitive
benefit
treatment
pepinemab
indicate
treatment
pepinemab
antibody
potentially
targets
cortical
centers
including
govern
cognition
first
sign
hd
often
chorea
cognitive
disturbances
generally
follow
later
disease
progression
believe
data
therefore
suggest
patients
somewhat
advanced
stage
hd
may
derive
greatest
benefit
zauderer
noted
insights
gained
study
also
suggest
pepinemab
might
important
treatment
option
alzheimer
neurodegenerative
diseases
known
primarily
affect
frontal
cortex
impact
cognition
previously
reported
imaging
data
indicate
brain
regions
affected
pepinemab
treatment
company
accordingly
initiated
screening
expects
begin
enrolling
patients
month
new
alzheimer
disease
study
pepinemab
clinical
sites
united
states
line
company
ongoing
efforts
alzheimer
well
head
neck
cancer
company
also
intends
examine
appropriate
prioritize
balance
budget
dr
zauderer
concluded
profoundly
grateful
patients
families
initiative
enthusiasm
participating
study
courage
confronting
burdens
study
two
endpoints
family
two
cognitive
assessments
huntington
disease
cognitive
assessment
battery
clinical
global
impression
change
cgic
although
study
meet
endpoints
results
two
cognitive
assessments
demonstrated
strong
trend
beneficial
change
ots
ptap
cognitive
assessments
reflect
changes
planning
ability
memory
associated
disease
progression
similarly
trend
benefit
cgic
show
statistically
significant
difference
placebo
groups
possibly
due
small
group
size
phase
study
pepinemab
remarkably
low
treatment
discontinuation
study
rates
extended
month
treatment
period
additional
results
including
broader
examination
motor
activity
outcomes
smaller
group
prodromal
subjects
reported
detail
upcoming
huntington
study
group
conference
october
subsequent
medical
conferences
conference
call
details
vaccinex
management
host
conference
call
webcast
today
september
edt
access
call
webcast
please
click
signal
trial
signal
study
evaluate
safety
efficacy
pepinemab
potential
treatment
people
huntington
disease
devastating
neurodegenerative
disease
currently
effective
disease
modifying
treatment
study
two
sequential
cohorts
primary
outcome
cohort
safety
pepinemab
appeared
additional
data
signal
cohort
demonstrated
pepinemab
treatment
results
increase
signal
measure
brain
metabolic
activity
primarily
cortical
regions
contrast
decrease
observed
placebo
group
described
natural
history
neurodegenerative
diseases
design
subsequent
cohort
b
informed
results
cohort
enrolled
subjects
early
manifest
patients
cohort
late
prodromal
subjects
cohort
randomized
treatment
least
months
duration
pepinemab
pepinemab
also
known
humanized
monoclonal
antibody
binds
blocks
activity
semaphorin
extracellular
signaling
molecule
regulates
migration
function
immune
inflammatory
cells
preclinical
studies
demonstrated
biological
activities
associated
antibody
blockade
promote
immune
cell
infiltration
tumors
prevent
neurological
damage
neuroinflammatory
neurodegenerative
disease
models
vaccinex
focused
development
pepinemab
treatment
cancer
neurodegenerative
diseases
including
huntington
alzheimer
disease
previously
announced
encouraging
results
obtained
study
pepinemab
combination
avelumab
checkpoint
inhibitor
cell
lung
cancer
new
collaboration
merck
test
combination
pepinemab
pembrolizumab
head
neck
cancer
expected
begin
early
pepinemab
investigational
new
drug
yet
approved
food
drug
administration
fda
regulatory
authorities
indication
vaccinex
vaccinex
immunotherapy
company
engaged
discovery
development
targeted
biotherapeutics
treat
serious
diseases
conditions
unmet
medical
needs
including
cancer
neurodegenerative
diseases
autoimmune
disorders
currently
active
clinical
trials
cell
lung
cancer
huntington
alzheimer
disease
recently
announced
collaboration
merck
combination
therapy
pepinemab
pembrolizumab
head
neck
cancer
vaccinex
based
rochester
new
york
forward
looking
statements
extent
statements
contained
press
release
descriptions
historical
facts
regarding
vaccinex
vaccinex
us
statements
reflecting
management
current
beliefs
expectations
statements
include
limited
statements
plans
expectations
objectives
respect
huntington
alzheimer
disease
cancer
clinical
trials
use
pepinemab
statements
identified
words
may
appears
expect
anticipate
estimate
intend
hypothesis
potential
advance
similar
expressions
negatives
well
words
expressions
referencing
future
events
conditions
circumstances
statements
involve
substantial
risks
uncertainties
could
cause
research
development
programs
clinical
development
programs
future
results
performance
achievements
differ
significantly
expressed
implied
statements
risks
uncertainties
include
among
others
uncertainties
inherent
execution
cost
completion
preclinical
clinical
trials
uncertainties
related
regulatory
approval
risks
related
dependence
lead
product
candidate
pepinemab
matters
could
affect
development
plans
commercial
potential
product
candidates
except
required
law
assume
obligation
update
statements
discussion
factors
could
cause
future
results
differ
materially
statement
see
section
titled
risk
factors
periodic
reports
filed
securities
exchange
commission
sec
risks
uncertainties
described
form
dated
march
subsequent
filings
sec
investor
contact
jeremy
feffer
lifesci
advisors
llc
jeremy
media
contact
cait
williamson
lifesci
communications
llc
cait
